Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: The rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study

Arthritis and Rheumatology

Volumn 67, Issue 7, 2015, Pages 1718-1728

  Rollefstad, S ^a   Ikdahl, E ^a   Hisdal, J ^b   Olsen, I C ^a   Holme, I ^c   Hammer, H B ^a   Smerud, K T ^d   Kitas, G D ^e   Pedersen, T R ^c,f   Kvien, T K ^a   Semb, A G ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Smerud Medical Research International AS   (Norway)

^e DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHROPATHY; ARTICLE; B SCAN; CARDIOVASCULAR PARAMETERS; CAROTID ATHEROSCLEROSIS; CAROTID PLAQUE HEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ACUTE CORONARY SYNDROME; BLOOD; CAROTID STENOSIS; COMPLICATION; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CAROTID STENOSIS; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RISK FACTORS; SPONDYLITIS, ANKYLOSING; SULFONAMIDES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84933073421     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39114     Document Type: Article

References (39)

1. Semb AG, Rollefstad S, van Riel P, Kitas GD, Matteson EL, Gabriel SE., Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Ann Rheum Dis 2014; 73: 1284-8.
2. Gonzalez A, Maradit KH, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, et al., The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7.
3. Solomon DH, Peters MJ, Nurmohamed MT, Dixon W., Motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1675-83.
4. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223: 1-68.
5. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al., Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29: 1702-8.
6. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al., Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249-56.
7. Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincon I., Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011; 63: 1211-20.
8. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al., Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87.
9. Kang S, Wu Y, Li X., Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004; 177: 433-42.
10. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, et al., Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J 2013; 34: 3182-90.
11. Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG., Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis 2013; 72: 1968-74.
12. Van Gammeren AJ, van Gool N, de Groot MJ, Cobbaert CM., Analytical performance evaluation of the Cobas 6000 analyzer: special emphasis on trueness verification. Clin Chem Lab Med 2008; 46: 863-71.
13. Friedewald WT, Levy RI, Fredrickson DS., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
14. Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Holme I, et al., Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann Rheum Dis 2014. E-pub ahead of print.
15. Semb AG, Rollefstad S, Provan SA, Kvien TK, Stranden E, Olsen IC, et al., Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013; 40: 359-68.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. Van der Heijde DM., How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5.
18. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al., Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24.
19. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Liapis CD., Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg 2010; 51: 114-21.
20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
21. Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H, et al., Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011; 70: 812-7.
22. Midtbo HB, Gerdts E, Kvien TK, Olsen IC, Hirth A, Davidsen ES, et al., Disease activity and left ventricular structure in patients with rheumatoid arthritis. Rheumatology (Oxford) 2015; 54: 511-9.
23. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
24. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [published erratum appears in JAMA 2005;294:3092]. JAMA 2005; 294: 2437-45.
25. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
26. Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, et al., Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64: 2836-46.
27. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
28. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J., Insulin resistance in rheumatoid arthritis: the impact of the anti-TNFα therapy. Ann N Y Acad Sci 2010; 1193: 153-9.
29. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK., Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-8.
30. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307.
31. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al., Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50: 518-31.
32. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al., Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82.
33. Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, et al., Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-α blockers: a two-year prospective observational study. Joint Bone Spine 2014; 81: 421-5.
34. De Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al., Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;(23 Suppl 1): III33-8.
35. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF., Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
36. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ., Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5.
37. Johri A, Hetu MF, Nambi V., Carotid plaque or CIMT: what is the future for carotid US imaging? Curr Cardiovasc Risk Rep 2014; 8: 1-8.
38. Wyman RA, Mays ME, McBride PE, Stein JH., Ultrasound-detected carotid plaque as a predictor of cardiovascular events. Vasc Med 2006; 11: 123-30.
39. Naqvi TZ, Lee MS., Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging 2014; 7: 1025-38.